Trinity Biotech Attending 84th Scientific Sessions of the American Diabetes Association
Trinity Biotech (Nasdaq: TRIB), a commercial-stage biotechnology firm specializing in diabetes management solutions and diagnostics, announces its senior management will attend the 84th Scientific Sessions of the American Diabetes Association. The event is scheduled for June 21-24, 2024, in Orlando, Florida. Trinity Biotech aims to advance its continuous glucose monitoring (CGM) biosensor technology and plans to host meetings with key stakeholders and potential partners. Interested parties can contact Biosensors@trinitybiotech.com for more information.
- Trinity Biotech's management team will attend the prestigious 84th Scientific Sessions of the American Diabetes Association, indicating active engagement in the industry.
- The company plans to host meetings with key stakeholders and potential partners, which may lead to new collaborations and business opportunities.
- The focus on advancing the next generation of its recently acquired CGM biosensor technology suggests ongoing development and innovation in diabetes management solutions.
- The press release lacks specific financial data or performance metrics, leaving investors without concrete information on the company's financial health.
- There is no mention of any new product launches or immediate marketable advancements, which might be seen as a lack of short-term catalysts for stock price improvement.
- The announcement does not address potential risks or challenges associated with the development and commercialization of the CGM biosensor technology.
DUBLIN, June 10, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, announces that its senior management team plans to attend the 84th Scientific Sessions of the American Diabetes Association in Orlando Florida, taking place on June 21-24, 2024.
Management plans to host meetings with key stakeholders and potential partners as it works to advance the next generation of its recently acquired continuous glucose monitoring (CGM) biosensor technology. Interested parties are invited to reach out for more information by emailing Biosensors@trinitybiotech.com. To learn more about Trinity’s CGM, please visit https://cgm.trinitybiotech.com
About Trinity Biotech
Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com
| Contact: | Trinity Biotech plc Gary Keating, Ph.D. (353)-1-2769800 | LifeSci Partners, LLC Eric Ribner (1)-646-751-4363 E-mail: investorrelations@trinitybiotech.com |
FAQ
What event will Trinity Biotech's management attend in June 2024?
What is Trinity Biotech's focus at the 84th Scientific Sessions?
How can interested parties get more information about Trinity Biotech's attendance at the ADA event?
What is the stock symbol for Trinity Biotech?
